 |
[Alpha Biz=(Chicago) Reporter Paul Lee] Samsung BioLogics, which recorded an earning surprise in the second quarter, surged nearly 9%.
On the KOSPI market on the 27th, Samsung BioLogics closed at 791,000 won, up 64,000 won (8.80%) from the previous day. After starting trading at 744,000 won, which rose 2.34%, the increase was boosted by buying. It is the first time that Samsung BioLogics' stock price has risen more than 8% since May 2021.
Individuals poured out more than KRW 120 billion in sales, but foreigners made a net purchase worth KRW 72 billion and institutions made KRW 54.5 billion, raising stock prices. On top of that, program purchases have also contributed to the influx of nearly 55 billion won.
It was a surprise performance in the second quarter that led to a sharp rise in stock prices. Samsung BioLogics' sales in the second quarter were 866.185 billion won and operating profit was 253.439 billion won, exceeding consensus sales of 807.1 billion won and operating profit of 227.9 billion won by 7.3% and 11.2%, respectively.
Alphabiz Reporter Paul Lee(hoondork1977@alphabiz.co.kr)
